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Abstract: Ulcerative colitis (UC) is a chronic inﬂ  ammatory condition of unclear etiology 
affecting the large bowel, most commonly the rectum and extending proximally in a continuous 
fashion. The overall principle in the pathophysiolgy of ulcerative colitis is the dysregulation of 
the normal immune system against an antigenic trigger leading to a prolonged mucosal inﬂ  am-
matory response. The diagnosing of UC is made by combining the clinical picture, tissue biopsy 
with the endoscopic appearance of mucosal ulceration, friable, edematous, erythematous granular 
appearing mucus. The approach to therapy of UC has been dependent on severity of symptoms 
with frontline therapy being salicylate based sulfasalazine. Newer formulations of salicylates 
based drugs with fewer side-effects have been developed. These are free of the sulphur component 
and are composed of 5-ASA, without the sulfapyridine carrier molecule. Mesalamine is one 
of these 5-ASA based agents that are currently available and indicated for treatment of UC. In 
mild/moderate active disease mesalamine has response rates between 40%–70% and remission 
rates of 15%–20%. Considering that the efﬁ  cacy of 5-ASA is dose dependent, 4.8 g/day and 2.4 
g/day have been shown to be the optimal dosages for mild-moderate distal active disease and 
for maintenance therapy, respectively. Patients with moderately active ulcerative colitis treated 
with 4.8 g/d of mesalamine are signiﬁ  cantly more likely to achieve overall improvement at week 
6 compared to patients treated with 2.4 g/d. In the setting of left-sided distal colitis (proctitis), 
topical (rectal) formulations have been found to be superior to oral aminosalicylates at induc-
ing remission. Mesalamine has been shown to be safe in short term use with a dose-response 
efﬁ  cacy without dose-related toxicity.
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Introduction
Ulcerative colitis (UC) is a chronic inﬂ  ammatory condition of unclear etiology 
affecting the large bowel, most commonly the rectum and extending proximally in a 
continuous fashion. Patients often present with abdominal pain, diarrhea and may also 
manifest other systemic features of fever and weight loss. The overall incidence and 
prevalence rates for UC range from 3 to 15:100,000 and 50–80:100,000, respectively, 
with higher rates reported in the industrial world (Stevenson and Korzenik 2003). The 
prevalence in the United States has been reported as high as 229 cases per 100,000, 
with approximately 25,000 new cases a year (Loftus et al 2000). It can affect any 
age group; however, it is more common in younger populations with a peak onset 
between 15 and 25 years old. There is an equal incidence found in both genders with 
bimodal incidence commonly seen in IBD. In the United States, African–Americans 
have the lowest incidence rate of 1.4 per 100,000 while Jews have the highest of 13 
per 100,000.Therapeutics and Clinical Risk Management 2007:3(5) 894
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Etiology
Ulcerative colitis is characterized as an idiopathic disease, 
however various possible etiologies have been proposed. The 
major hypotheses regarding the etiology of UC have included 
infection, allergy to dietary components, immune responses to 
bacterial or self-antigens and environmental causes. Infectious 
causes include pathogenic microbial antigenic triggers that 
have yet to be identiﬁ  ed. However, it appears to be more likely 
that normal intestinal microﬂ  ora as opposed to pathogenic 
organisms may have a signiﬁ  cant role in development of IBD 
(Stevenson and Korzenik 2003). Defective colonic mucosa 
and abnormal intestinal epithelial permeability may increase 
the access of luminal dietary and bacterial products to the 
mucosa (Shanahan 2001). Environmental causes have been 
proposed in relationship to the prevalence of IBD (Bernstein 
et al 2006). However, there has been little evidence that any 
particular food components play a primary role in the etiology 
of the disease. Fecal stream has been shown to be a factor in 
promoting further mucosal inﬂ  ammation and therefore the 
importance of the role of gut ﬂ  ora in IBD has been brought 
forward. While smoking has been related to increased risk 
for activity of disease in Crohn’s disease, it has demonstrated 
a protective effect in UC with the highest risk of developing 
UC in the ﬁ  rst 2 years after cessation of smoking (Stevenson 
and Korzenik 2003).
Genetic studies have suggested that ﬁ  rst-degree relatives 
have increased absolute risk of 7 percent, which is 4 to 20 times 
as higher than compared to the normal population (Orholm and 
Munkholm 1991). However, there is a low concordance rate 
in monozygotic twins, indicating that environmental factors 
are also involved (Bernstein et al 2006). Genetic linkage 
studies suggest an association between ulcerative colitis and 
the human leukocyte antigen (HLA) genes on chromosomes 
12 and 16, but specific responsible genes are not well 
deﬁ  ned (Stevenson and Korzenik 2003). Genetic alteration 
experiments performed in germ-free environments have not 
yielded colitis, thus supporting the theory of a multifactorial 
cause of UC (Boden and Cho 2003).
Pathophysiology
The overall principle in the pathophysiolgy of ulcerative 
colitis is the dysregulation of the normal immune system 
against an antigenic trigger. The aggregate effect of genetic, 
environmental, and other processes is a sustained activation 
of the mucosal immune response (Podolosky 2002). A state 
of altered immune regulation leading to prolonged mucosal 
inﬂ  ammatory response and thus resulting in the recruitment 
of leukocytes from the gut vasculature (Powrie 1995) exists 
in UC. The mucosa in patients with UC may be dominated 
by CD4+ non-T helper lymphocytes generating a humoral 
immune proﬁ  le. Defective colonic mucosa allows the access 
of luminal dietary and bacterial products to the mucosa 
(Podolosky 2002). The possible antigenic triggers currently 
proposed include microbial pathogens, nonpathogenic micro-
bial agents, dietary antigens and an autoimmune mechanism. 
Animal models using knock out genes that affect the mucosal 
immune system or epithelial integrity have resulted in intes-
tinal mucosal inﬂ  ammation in non germ-free environments 
(Strober et al. 1998). This therefore supports the fact that the 
presence of luminal bacteria and the absence of regulatory 
proteins in the mucosal immune system are generally required 
for development of intestinal inﬂ  ammation. Furthermore, an 
uncontrolled immune activation with failure of suppression 
is a commonly explained mechanism of inﬂ  ammatory bowel 
disease. Proinﬂ  ammotory mediators, or cytokines, are also 
known to play an important role in UC, with evidence to sup-
port increased levels of IL-1, IL-6, IL-8 and tumor necrosis 
factor (TNF-a) (Fiocchi 1998).
Clinical presentation and diagnosis
The most common clinical course in patients with ulcerative 
colitis is chronic intermittent with approximately 10% of 
cases presenting as acute fulminating (Powell-Tuck and 
Truelove 1963) (Figure 1).
Between episodes, patient may be free of symptoms. 
Symptoms are related to the extent of the disease, with 
common clinical features being intermittent rectal bleeding, 
tenesmus, crampy pain, passage of mucous, and mild diar-
rhea. When the disease is severe, more systemic features can 
be seen. These include fevers, weight loss, severe abdominal 
pain, anemia, and malnutrition. Based on clinical and endo-
scopic ﬁ  ndings the disease is characterized as to its severity 
and extent (Kornbluth and Sachar 2004). This allows clini-
cians to predict the extent of involvement and better assess the 
level of acuity of the patient. The most severe complication 
from an UC ﬂ  are is toxic megacolon, which often requires 
surgery. If the disease is conﬁ  ned to the rectum, the patient 
may only complain of urgency and primarily tenesmus with 
bloody bowel movements and diarrhea.
Anatomic distribution of disease by endoscopic evaulation 
can be used to describe the degree of involvement and the 
state of activity. Almost all cases of UC have rectal involve-
ment. Ulcerative proctitis is a disease limited to the rectum, 
whereas proctosigmoiditis extends to the mid sigmoid colon, 
left sided colitis extends to splenic ﬂ  exure (30%) and exten-
sive colitis extends beyond splenic ﬂ  exure but not reaching Therapeutics and Clinical Risk Management 2007:3(5) 895
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cecum (20%) and pancolitis extends all the way to cecum. 
The various states of activity can be described as relapsing, 
mild/moderate active, severe active and remission, while the 
degree of severity of UC is described as mild, moderate, and 
severe and distinguished by frequency of bowel movements, 
abdominal symptoms, extent of colonic involvement, presence 
of fever or bleeding per rectum (Table 1). Mild is deﬁ  ned as 
less than 4 bowel movements a day, normal ESR and no signs 
of systemic toxicity and fulminant is deﬁ  ned as greater than 
10 bowel movements a day, continuous bleeding, systemic 
toxicity, abdominal tenderness, transfusion requirement, and 
colonic dilation on x-ray. Therefore, once the diagnosis can be 
conﬁ  rmed and the degree of involvement and activity can be 
determined, the speciﬁ  c treatment regimen is initiated.
The diagnosis of UC is made by combining the clinical 
picture with the endoscopic appearance of mucosal ulceration, 
friable, edematous, erythematous granular appearing mucosa, 
often described as “sand sprinkled on a moist surface”. 
Biopsy results suggestive of UC include crypt abscesses, 
superﬁ  cial microulcerations, and inﬂ  ammatory inﬁ  ltrate. Other 
histological ﬁ  ndings include widespread crypt distortion and 
loss, and marked goblet cell mucin depletion. With chronic 
inﬂ  ammation the architecture of the crypts are distorted, 
becoming branched, shortened and atrophied. One must 
remember that the clinical presentation and endoscopic 
ﬁ  ndings are nonspeciﬁ  c and infectious and other acute self-
limiting causes of colitis must always be excluded.
Treatment of ulcerative colitis
Introduction
The approach to therapy of UC has been dependent on severi-
ty of symptoms with frontline therapy being aminosalicylates. 
The intolerance of sulfasalazine being a restrictive factor, 
newer formulations have been developed which are free of 
the sulphur component and have better side-effect proﬁ  le. 
These drugs are composed of 5-ASA, the active moiety of 
sulfasalazine, without the sulfapyridine carrier molecule that 
is usually the main cause of the side effects. Mesalamine 
is one of the 5-ASA based agents currently available and 
indicated for treatment of UC. This review will examine the 
evidence for 5-ASAs in the treatment of ulcerative colitis. 
The different 5-ASA formulations will be discussed and 
compared and the current data available regarding efﬁ  cacy, 
dosages and side effect proﬁ  le will be presented.
Sulfasalazine
Sulfasalazine (Pharmacia & Upjohn Company, Kalamazoo, 
MI, USA), ﬁ  rst developed in 1942, has been the parent 
Figure 1 Clinical course of ulcerative colitis.  Adapted from data: Powell-Tuck and Truelove (1963).
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aminosalicylate in use for over 60 years (Hanauer 2004) 
and consists of 5-aminosalyclic acid linked by an azo bond 
to sulfapyridine (Figure 2). It combines an antibacterial 
agent (sulfapyridine) with an anti-inﬂ  ammatory component 
(5-ASA). The sulfonamide moiety acts as a carrier to deliver 
the active component 5-ASA to the colon where it is released 
by bacterial action. Sulfasalazine is metabolized by colonic 
bacterial enzymes to produce the two active byproducts. 
Sulfapyraidine is metabolized by the liver and excreted in 
the urine whereas the 5-ASA component is acetylated by the 
colonic epithelium (Rochester and Abreu 2005). The original 
indication for 5-ASA was for rheumatoid arthritis, however it 
was subsequently found to be efﬁ  cacious in ulcerative colitis. 
Misiewicz et al (1965) published the ﬁ  rst placebo controlled 
maintenance trial in 1965 randomizing patients to receive 
sulfasalazine or placebo for one year. Seventy three percent 
of patients taking placebo relapsed compared to 21% taking 
the active drug, thus showing sulfasalazine to be highly 
efﬁ  cacious for the treatment of ulcerative colitis.
Due to the intolerance of sulfasalazine being a restrictive 
factor in optimizing the therapeutic dosage, more tolerable 
mesalamine-based drugs have been developed void of the 
sulphur component. These new formulations are composed 
of 5-ASA, the active moiety of sulfasalazine, without the 
poorly tolerated sulfapyridine carrier molecule. The newer 
generation aminosalicylates allow for targeted delivery with 
reduced side effects observed with sulfasalazine. These new 
formulations also allow for earlier release more proximally in 
the small intestine. An added beneﬁ  t also includes variablility 
in the pH dependent site of release of various aminosalicy-
lates (see Table 2).
A variety of different mechanisms have been proposed by 
which aminosalicylates work in inﬂ  ammatory bowel disease. 
The main mechanism includes the inhibition of cyclooxygenase 
and lipoxygenase pathways to reduce the production of pros-
taglandins and leuokotrienes, respectively (Kaiser et al 1999). 
Mesalamine also reverses the antiproliferative effects of 
TNF-alpha thus disrupting the effect of cytokines by reducing 
intestinal cell transcription of inﬂ  ammatory mediators (Kaiser 
et al 1999). Other processes described include inhibition of 
platelet activating factor and production of oxygen radicals 
and other anti-inﬂ  ammatory factors (Egan et al 1999; Hanauer 
2004). By reducing inﬂ  ammatory prostaglandin production and 
the formation of other potent chemotactic substances including 
leukotriene B4 and certain hydroxy fatty acids (Grisham 1994), 
mesalamine plays a signiﬁ  cant role in halting the perpetuation 
of a chronic inﬂ  ammatory state.
Different preparations have been designed in accordance 
to delivery site depending where the highest activity of disease 
is located. There have been two major forms of delivery 
systems currently available. One method is coating 5-ASA 
with a pH sensitive resin or a semipermeable membrane. An 
alternative approach is a prodrug system which is to link the 
5-ASA with another molecule by an azo bond (Figure 2). The 
enteric coated formulations include Asacol (Procter & Gamble 
Pharmaceuticals, Cincinatti OH, USA), coated with Eudragit S, 
which dissolves at pH 7.0 or above since pH reaches this level 
in the distal ileum and colon. Salofalk (Dr Falk Pharma GmbH, 
Feiburg, Germany), coated with Eudragit L, releases the 
active ingredient at pH 6.0 and above. Pentasa (Shire US, Inc., 
Wayne PA, USA) is a time released formulation containing a 
semipermeable membrane and releases the drug at pH greater 
than 6.0. Olsalazine (Dipentum; Celltech Parmaceuticals, Inc., 
Rochester NY, USA) and balsalazide (Salix Pharmaceuticals, 
Inc., Morrisville, NC, USA) are prodrugs, where one 5-ASA 
is bound covalently through an azo linkage to another 5-ASA 
and the release of the 5-ASA is by bacterial azo reduction in 
the colon. Variability may exist in the absorption of 5-ASA, 
most commonly due to the failing of the active drug to reach 
the appropriate pH in the small intestine. The therapeutic 
effect of these compounds is dependent on releasing of 
active drug in the colon which will therefore improve clinical 
response. Because of adherence issues, a newer high-strength 
1.2 gram mesalamine formulation has been developed which 
utilizes a multimatrix (MMX) technology to produce a slow 
and homogenous delivery of mesalamine to the entire colon 
and rectum (Prantera et al 2005). Once dissolved above pH 
of 7.0, the core reveals a hydrophilic matrix that turns into 
a gel mass upon exposure to intestinal ﬂ  uid, and pieces of 
the gel are distributed in different parts of the colon. With 
this higher concentration tablet and slow dissolution, the 
aim is to increase adherence by minimizing the number 
Table 1 Classiﬁ  cation of ulcerative colitis
Mild Moderate    Severe  Fulminant
Less than  More than four   More than  More than ten
four stools  stools daily  six bloody  bowel movements
daily with or   Minimal signs of   stools daily  Continuous
without blood  toxicity  Evidence of  bleeding
No systemic      toxicity  Toxicity
signs of     demonstrated  Abdominal
toxicity   by  fever,  tenderness
Normal ESR    tachycardia,  distension
    anemia, elevated  Blood transfusion
   ESR  requirement
     Colonic  dilatation
     on  abdominal  ﬁ  lm
Adapted from (Kornbluth and Sachar 2004).Therapeutics and Clinical Risk Management 2007:3(5) 897
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of tablets required. Another improved delivery method is 
a micropellet formulation, provided as individual sachets 
containing granules, with less frequent (2 packets twice a day) 
dosing. Studies have shown non-inferiority of the micropellet 
formulation compared to tablets in terms of clinical remission 
within 8 weeks (Cohen 2006).
5-ASA in active disease
Mesalamine
Although there is no evidence of greater clinical response 
of mesalamine versus other 5-ASA preparations, there is 
adequate data to support the effectiveness of mesalamine in 
mild/moderate active disease with response rates between 
40%–70% and remission rates of 15%–20% (Snisky et al 
1991; Kornbluth and Sachar 2004; Hanauer et al 2005). 
However, in studies comparing 5-ASA with sulfasalazine, 
there was no increased effectiveness of 5-ASA over sulfasala-
zine (Sutherland and MacDonald 2006). Two studies have 
shown that delayed – release mesalamine showed signiﬁ  -
cant beneﬁ  t compared with placebo (Schroeder et al 1987; 
Sninsky et al 1991). It was demonstrated that mesalamine 
4.8 g/d had a higher complete response compared to those 
taking placebo (24% vs 5% p = 0.047) as well as higher 
partial response (50% vs 13%, p value not given) (Kane and 
Bjorkman 2003). The clinical response was based on prede-
termined criteria that included stool frequency, rectal bleed-
ing, sigmoidoscopic appearance of the mucosa. A complete 
response was deﬁ  ned as total resolutions of all symptoms, 
whereas a partial response was a substantial but incomplete 
improvement in clinical parameters. The absolute beneﬁ  t 
increase (ABI) based on overall response for mesalamine 
4.8 g/d over placebo was 56% with a number needed to treat 
5-aminosalicylic acid
Sulfasalazine
balsalazide
olsalazine
Figure 2 Chemical structures of 5-ASA preparations.Therapeutics and Clinical Risk Management 2007:3(5) 898
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(NNT ) of two. Responses have generally been dose-related 
with up to 80% of patients who receive daily doses of 4–6 g 
manifesting complete clinical remission or signiﬁ  cant clinical 
improvement within 4 weeks (Kornbluth and Sachar 2004). 
Studies employing doses of 1.6 g/d and 2.4 g/d conﬁ  rmed 
overall clinical response rates higher than placebo.
According to the American College of Gastroenterology 
practice guidelines on ulcerative colitis, mild-to moderate 
extensive colitis should be treated with oral sulfasalazine 
titrated up to 4–6 g per day or an alternative aminosalicylate 
dose up to 4.8 g per day (Grade A evidence) (Kornbluth 
and Sachar 2004). Patients with only moderately active 
ulcerative colitis treated with 4.8 g/d of mesalamine were 
signiﬁ  cantly more likely to achieve overall improvement at 
week 6 compared to patients treated with 2.4 g/d (Hanauer 
et al 2005) (see Figure 3). This result was based on a double-
blinded, controlled trial of 386 patients randomized to either 
2.4 g/day or 4.8 g/day for 6 weeks. The primary endpoint 
was the proportion of patients in each arm achieving overall 
improvement from baseline at week 6. Overall improvement 
was deﬁ  ned as either complete resolution of signs and symp-
toms or a clinical response to therapy. Results demonstrated 
improvement in predetermined clinical parameters in 57% 
of patients treated with 2.4 g/day and 72.4% treated with 4.8 
g/day (p = 0.0384).
In patients with extensive mild/moderate active UC 
deﬁ  ned by involvement beyond the splenic ﬂ  exure, Marteau 
et al (2005) demonstrated adding a mesalamine enema to an 
oral regimen would provide additional beneﬁ  t for patients 
with extensive mild/moderate active UC. A randomized 
double blind study was conducted in 127 ambulatory patients 
receiving 4 g/day oral mesalamine. Patients were randomized 
to either receiving 1 g mesalamine enema nightly versus 
placebo and disease activity was assessed at 4 and 8 weeks. 
Disease activity was assessed using endoscopic signs of 
improvement and clinical features of response. Brieﬂ  y, 
clinical and endoscopic features of response include decrease 
stool frequency, decrease episodes of rectal bleeding, physi-
cian global assessment, and decreased erythema, friability, 
and ulcerations on endoscopy. Objective scoring system 
was established for different stages of the clinical features 
and accordingly the endpoints of remission and clinical 
improvement were deﬁ  ned. The combination therapy of 
oral and enema mesalamine treatment was shown to be 
superior to oral alone in terms of both remission and improve-
ment. Improvement was obtained in 89% of mesalamine 
enema group versus 62% of the placebo group at week 4 
(p = 0.0008). At week 8, 86% of the mesalamine enema 
group versus 68% of the placebo group (p = 0.026) showed 
improvement (Marteau et al 2005) (see Figure 4).
There are approximately 10%–20% of patients who 
can be described to be in a chronically active inﬂ  ammatory 
state, becoming steroid dependent. There is very little data 
evaluating the efﬁ  cacy of 5-ASA for treatment of steroid 
dependent ulcerative colitis. Ardizzone et al (2005) com-
pared the efﬁ  cacy of 5-aminosalicylic acid and azathioprine 
Table 2 Different preparations of mesalamine for UC therapy
  Delayed release  Slow   Prodrugs  Prodrugs  Topicals  Sulfasalazine
   release       
Formulation Asacol  Pentasa  Olsalazine  Balsalazide  Mesalamine  enema
Preparation  Enteric coated 400 mg  Capsule   Capsule   Capsule   4 g/60 ml rectal      
    250 mg or   250 mg  750 mg  suspension     
    500 mg      1 g rectal  
         suppository 
Solubility  pH > or equal 7  Continuous   pH   pH    
   release  independent  independent    
Location of  Terminal ileium  Small bowel,   Colon  Colon  Rectum  Small bowel, 
delivery   colon       colon
Maintenance of   2–4 g/day  2–4 g/day  1 g/day  2.25 g TID  4 g/day  2 g/day
remission          
Mild to moderate   2.4 to 4.8 g/daily  2–4 g/daily  2–3 g/daily  6.75 g/day  4 g/per rectum  3–4 g/day
Active disease  TID dosing   QID dosing  BID dosing  TID dosing   BID  QID dosing
proctitis         1  g/BID 
          Active disease: 1 g  
          BID (suppository) or 4  
          g enema qd or BID 
          Maintenance: 1 g supp. 
          Daily or prn symptomsTherapeutics and Clinical Risk Management 2007:3(5) 899
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in inducing remission of steroid dependent ulcerative 
colitis. Success in treatment was deﬁ  ned by clinical and 
endoscopic remission with steroid discontinuation, with 
azathioprine being more effective than 5-ASA in inducing 
clinical and endoscopic remission and avoiding long term 
steroid dependence. However in terms of side effects, dose 
reduction interventions took place in 14% of patients in the 
azathioprine group due to leukopenia and abnormal liver 
function tests.
Prodrugs
Balsalazide, which is pH-dependent, delayed release and 
slow release mesalamine preparation has also shown 
improvement in clinical symptoms in acute mild to moderate 
ulcerative colits (Pruitt et al 2002). Data has revealed that in 
newly diagnosed patients with less than 40 cm involvement 
improvement of symptoms occurred in a median time of 11 
days. The authors did demonstrate that balsalazide patients 
showed improvement in sigmoidoscopic appearance, stool 
frequency, rectal bleeding, and physician’s global assessment 
score by 14 days. However, overall no statistically signiﬁ  -
cance differences between mesalamine and balsalazide were 
detected at the end of week 8 of treatment. Mansﬁ  eld et al 
(2002) compared the safety and efﬁ  cacy of sulfasalazine 3 g 
with balsalazide 6.75 g in the initial daily treatment of mild 
to moderate ulcerative colitis and reported that balsalazide 
is effective as the sole treatment in this patient population 
with fewer withdrawals due to side-effects compared to the 
sulfasalazine group taking 3 g/day.
5-ASA in maintenance of remission
Seventy percent of patients with ulcerative colitis given no 
treatment can expect to experience a relapse over a 12-month 
period. As early as 1965 it was shown that sulfasalazine 
is effective in maintenance therapy in ulcerative colitis 
(Misiewicz et al 1965), and newer generation 5-ASAs includ-
ing olsalazine and balsalazine have shown relapse prevention 
properties virtually the same as, but not greater than, those of 
equivalent doses of sulfasalazine (Kornbluth and Sachar 2004). 
A Cochrane Database analysis of 2,124 patients (Sutherland 
and MacDonald 2006) showed 5-ASA to be superior to pla-
cebo with regard to all measured outcome variables. Dose 
response trend for 5-ASA was again conﬁ  rmed, and the odds 
ratio of 5-ASA compared to sulfasalazine was 0.83 (95% CI 
0.60 to 1.13) for failure to induce global/clinical improvement 
or remission, and 0.66 (95% CI 0.42 to 1.04) for the failure to 
induce endoscopic improvement (Sutherland and Macdonald 
2003). There was no statistical difference in maintenance of 
remission between 2.4 g/d compared to 1.2 g/d after one year 
(30). Although the increased dose did not appear to reduce the 
incidence of relapse of UC over a period of 1 year, the authors 
report that the increase dose was beneﬁ  cial in overall delaying 
Figure 3 Double blinded controlled trial of 386 patients randomized to either 2.4 g/day or 4.8 g/day for 6 weeks. Overall improvement deﬁ  ned as either complete resolu-
tion of signs and symptoms or a clinical response to therapy. Results demonstrated improvement in clinical parameters in 72.4% of patients treated with 4.8 g/day and 57% 
treated with 4.8 g/day (p = 0.0384) Adapted from data: Hanuer et al (2005).
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relapses. Most comparison studies of mesalamine have shown 
increased efﬁ  cacy in remission with higher doses up to 4 g per 
day of aminosalicylates (Kornbluth and Sachar 2004).
Left sided ulcerative colitis/proctitis
There is overwhelming data to support the use of topical 
formulations of 5-ASA in distal left sided colitis. The 
question arises whether topical therapy alone is efﬁ  cacious 
or if topical therapy combined with oral mesalamine would 
produce higher response rates. A study to compare the 
efﬁ  cacy of mesalamine rectal suspension enema, Rowasa 
(Solvay Pahramceuticals, Inc., Marietta, GA, USA), alone, 
oral mesalamine (Asacol) alone, and the combination of 
enema and tablet in patients with distal UC found that the 
combination of oral and rectal mesalamine therapy was 
well tolerated and produced earlier and more complete 
relief of rectal bleeding than oral or rectal therapy alone 
(Safdi et al 1997) (see Figure 5). However, it has not been 
clearly deﬁ  ned whether this is a dose response effect or 
independently a beneﬁ  t of topical therapy.
Beclamethasone enemas in combination with 5-ASAs 
as well have favorable response in those patients who have 
failed treatment with oral 5-ASAs alone (D’Arienzo et al 
1998). However, a comprehensive meta-analysis performed 
of 67 studies reported that the therapeutic approach in 
left-sided ulcerative colitis and proctitis was dose dependent 
and topical mesalamine was superior to oral therapies and 
topical steroids (Cohen et al 2000). The meta-analysis also 
found topical mesalamine was superior in achieving remis-
sion compared to topical steroids with overall decreased 
patient costs.
In the setting of left-sided distal colitis (proctitis), topi-
cal (rectal) formulations were found to be superior to oral 
aminosalicylates at inducing remission (Cohen et al 2000) 
and the therapeutic effect of mesalamine was strongly 
correlated with its mucosal concentration (Frieri et al 2005). 
In patients with high relapse rate (as measured by at least 
four moderate to severe relapses in the preceding 2 years), 
the continuous use of topical mesalamine (4 g/day) with 
high oral dosage (3.2 g–4.8 g/day) signiﬁ  cantly decreased 
the total number of recurrences by increasing the mucosal 
concentration (Cohen et al 2000). A meta-analysis of ﬁ  ve 
controlled trials comparing rectal mesalamine with pla-
cebo for distal colitis showed superiority of mesalamine 
over placebo (Marshall and Irvine 1995). Slow release 1 g 
mesalamine suppositories used three times per week was 
compared with placebo in maintaining remission in patients 
with proctitis and the data reveled that slow release sup-
positories were also effective for preventing relaspses in 
ulcerative proctitis (Marteau et al 1998).
Addition of mesalamine enema to oral 4 g/d mesalamine therapy
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Figure 4   The combination therapy of oral and enema mesalamine treatment was shown to be superior to oral alone in terms of both remission and improvement. 
Improvement was deﬁ  ned by objective scoring method based on disease activity. Improvement was obtained in 89% of mesalamine group versus 62% of placebo group at 
week 4 (p = 0.0008).  At week 8, 86% of mesalamine enema group versus 68% of placebo group (p = 0.026) showed improvement. Adapted from data: Marteau et al (2004).Therapeutics and Clinical Risk Management 2007:3(5) 901
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Adverse effects of 5-ASAs
5-aminosalicylates have been shown to be in safe in short 
term use (Loftus et al 2003) with a dose-response efﬁ  cacy 
without dose-related toxicity. There is sufﬁ  cient data to 
demonstrate long-term safety with mesalamine at doses of 
up to 5 g daily (Cunliffe and Scott 2002). In clinical trials of 
active ulcerative colitis comparing mesalamine with placebo, 
the fraction of patients with adverse events ranged from 
13% to 73% with mesalamine vs. 22% to 61% with placebo 
(Loftus et al 2003). The most commonly reported adverse 
events with the 5-ASA formulations include headache, GI 
symptoms such as diarrhea, bloating, nausea. Other rare side 
effects include interstitial nephritis, hepatitis, pericarditis, 
pancreatitis, pneumonitis, dermatitis, myocarditis, and 
hematological disturbances (Ransford and Langman 2002) 
(Table 3). On occasion, drug holidays may be initiated until 
diarrheal symptoms resolve. Nephrotoxicity can be seen 
with any of the 5-ASA compounds. Considering that IBD 
affects younger population, it is reasonable to also evaluate 
its safety proﬁ  le in pregnancy. There has been no evidence 
of teratogenic effect or fetal toxicity with mesalamine 
(Diav-Citran et al 1998), placing it into a FDA category B 
for pregnancy.
A prospective controlled cohort study of pregnancy 
exposure to mesalamine in women with IBD was 
performed. Although the mean daily dose used by the 
cohort was 2.4 g/d, lower than customarily used for active 
treatment, no major teratogenic effects were observed. 
Marteau et al (2004) establishing guideline for treatment 
in pregnancy recommended choosing alternative treatments 
or monitoring echogenecity of the fetal kidney when 
requiring mesalamine at doses greater than 3 g/day. This 
is in part due to case report of severe fetal nephropathy 
during renal morphogenesis (Colombel et al 1994). It is 
important to note that compared to a matched control group 
Superiority in clinical symptomsof combination oral + rectal therapy vs. oral alone
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Figure 5  The combination of oral and rectal mesalamine therapy produced earlier and more complete relief of rectal bleeding than oral and rectal therapy alone. Pairwise 
analysis revealed that combination therapy resulted in signiﬁ  cantly fewer days to cessation of rectal bleeding compared with either the mesalamine enema (p = 0.04 general-
ized Wilcoxon test) or mesalamine tablet group (p = 0.002, generalized Wilcoxon test) alone.   Adapted from data: Safdi et al (1997).
Table 3 Side effects of mesalamine
Common Rare
Headache Interstitial  nephritis
Diarrhea Hepatitis
Bloating Pericarditis
Nausea Pancreatitis
Hypersensitivity Pneumoninitis
 Dermatitis
 Myocarditis
 Hematological  disturbances
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with nonteratogenic exposure, the cohort did have a higher 
incidence of preterm deliveries, decrease in mean maternal 
weight gain, and a decrease in mean birth weight. However 
this can be attributed to ongoing disease activity of UC 
as well (Diav – Citran et al 1998). No increase in these 
complications were noted when patients were in clinical 
remission during pregnancy.
5- ASAs in cancer prevention
Besides its therapeutic role in ulcerative colitis, 5-ASAs have 
been observed to have properties of chemoprevention for 
colon cancer. Since colorectal cancer has a higher incidence 
in patients with inﬂ  ammatory bowel disease than the general 
population, there has been great interest in determining 
whether antinflammatory drugs used to treat IBD have 
an effect on reducing colorectal cancer rates (Bernstein 
et al 2001). Two prospective studies have reported favorable 
effects of 5-ASA therapy on surrogate markers of colorectal 
cancer, such as rectal cell proliferation and apoptotic index 
(Bus et al 1999; Reinacher-Schick et al 2000). Although 
there have been no randomized trials, pooled results of 
observational studies support a protective association for 
5-ASAs and colorectal cancer (Velayos et al 2005). Van 
Staa et al (2005), using a study population of 18,969 patients 
from the General Practice Research Database in the UK, 
in a case control analysis, found that regular use of 5-ASA 
(1.6 g/d or higher) was associated with reduction in the risk of 
colorectal cancer in ulcerative colitis. They were also able to 
reproduce previous data which supports that mesalamine was 
associated with greater reduction in cancer risk compared to 
sulfasalazine. Rubin et al (2006) in a case control study of 26 
case reported 5-ASAs use of 1.2 g/d or more was associated 
with a 72% reduction in the odds of dysplasia and colorectal 
cancer (odds ratio 0.28 95% CI 0.09–0.085) and as the total 
dose of aminosalicylates increased, the odds of dysplasia and 
cancer decreased (p = 0.056).
Conclusion
Aminosalicylate therapy remains the foundation for treating 
colitis and maintaining remission in mild to moderate 
ulcerative colitis. Over the years new formulations have 
been developed to make this product more tolerable and 
efﬁ  cacious. Mesalamine, a 5-ASA is the active moiety 
of the precursor drug sulfasalazine, is signiﬁ  cantly more 
tolerable than its predecessor. Considering that the efﬁ  cacy 
of 5-ASA is dose dependent, 4.8 g/day and 2.4 g/day have 
been shown to be the optimal dosages for active disease and 
for maintenance therapy, respectively. As for left-sided distal 
disease, topical (rectal) formulation is superior in inducing 
remission.
Mesalamine is an excellent ﬁ  rst-line therapy for a step-
up approach in treating mild to moderate ulcerative colitis 
and for maintenance of remission. Furthermore, different 
modes of delivery have also been developed to enhance the 
therapeutic efﬁ  cacy of these products. Overall treatment deci-
sions should be based on the severity and extent of disease. A 
factor which will inﬂ  uence success of therapy is maximizing 
mucosal concentration of therapy by localizing the area of 
involvement and therefore utilizing the most appropriate 
delivery formulation. Compliance being a restrictive factor 
in treatment success, new formulations have been developed 
which will require less frequent dosing. Considering that UC 
is a chronic remitting active inﬂ  ammatory condition, patients 
will most likely need lifelong therapy.
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